{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:22:27Z","timestamp":1752283347510,"version":"3.37.3"},"reference-count":48,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/infdis\/jiz066","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T04:19:03Z","timestamp":1550463543000},"source":"Crossref","is-referenced-by-count":4,"title":["The Costs of Drugs in Infectious Diseases: Branded, Generics, and Why We Should Care"],"prefix":"10.1093","author":[{"given":"Sydney","family":"Costantini","sequence":"first","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8795-379X","authenticated-orcid":false,"given":"Rochelle P","family":"Walensky","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital, Boston"},{"name":"Divisions of Infectious Diseases and General Internal Medicine, Massachusetts General Hospital, Boston"},{"name":"Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"key\n\t\t\t\t2019031903071592200_CIT0001","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jama.2018.1150","article-title":"Health care spending in the United States and other high-income countries","volume":"319","author":"Papanicolas","year":"2018","journal-title":"JAMA"},{"year":"2017","author":"Prescription Justice","key":"key\n\t\t\t\t2019031903071592200_CIT0002"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0003","article-title":"Growth of health care spending slowed last year","author":"Pear","year":"6","journal-title":"New York Times"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0004","article-title":"The way to fix outrageous drug pricing in the US is simply to do what all other rich countries do","author":"Merelli","year":"2015","journal-title":"Quartz"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0005","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMp1612517","article-title":"Getting real about health care costs - a broader approach to cost stewardship in medical education","volume":"376","author":"Parikh","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0006","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jama.2013.8278","article-title":"Views of US physicians about controlling health care costs","volume":"310","author":"Tilburt","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0007","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/ACM.0000000000000791","article-title":"U.S. internal medicine residents\u2019 knowledge and practice of high-value care: a national survey","volume":"90","author":"Ryskina","year":"2015","journal-title":"Acad Med"},{"article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO Guideline. American Urological Association","year":"2017","author":"Sanda","key":"key\n\t\t\t\t2019031903071592200_CIT0008"},{"article-title":"Management of Crohn\u2019s disease in adults. American College of Gastroenterology","year":"2009","author":"Lichtenstein","key":"key\n\t\t\t\t2019031903071592200_CIT0009"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0010","first-page":"1","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis","volume":"49","author":"Mermel","year":"2009"},{"author":"US Department of Health and Human Services","key":"key\n\t\t\t\t2019031903071592200_CIT0011"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0012","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/536388a","article-title":"Busting the billion-dollar myth: how to slash the cost of drug development","volume":"536","author":"Maxmen","year":"2016","journal-title":"Nature"},{"author":"Statistica","key":"key\n\t\t\t\t2019031903071592200_CIT0013"},{"year":"2017","author":"United States Government Accountability Office","key":"key\n\t\t\t\t2019031903071592200_CIT0014"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0016","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1073\/pnas.1715368115","article-title":"Contribution of NIH funding to new drug approvals 2010\u20132016","volume":"115","author":"Galkina Cleary","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"year":"2016","author":"Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services","key":"key\n\t\t\t\t2019031903071592200_CIT0017"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0018","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0019","article-title":"The price of Sovaldi and its impact on the US healthcare system","author":"Hatch","year":"2015","journal-title":"Committee on Finance, United States Senate"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2055-6640(20)30691-9","article-title":"Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C","volume":"2","author":"Hill","year":"2016","journal-title":"J Virus Erad"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0021","article-title":"Hepatitis C treatment costs: what you should know","author":"Morris","year":"2018","journal-title":"Healthline"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0022","first-page":"CD008056","article-title":"Linezolid versus vancomycin for skin and soft tissue infections","author":"Yue","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"author":"Cleveland Clinic","key":"key\n\t\t\t\t2019031903071592200_CIT0023"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0024","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/cc13996","article-title":"Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus","volume":"18","author":"Patel","year":"2014","journal-title":"Crit Care"},{"author":"Pfizer Inc","key":"key\n\t\t\t\t2019031903071592200_CIT0025"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0026","unstructured":"Lessem E , VolpertL. An activist\u2019s guide to linezolid. Treatment Action Group. 2014. http:\/\/www.treatmentactiongroup.org\/sites\/default\/files\/201409\/Linezolid%20Fact%20Sheet%20V7%20LR.pdf. Accessed 29 August 2018."},{"year":"2017","author":"Pfizer Inc","key":"key\n\t\t\t\t2019031903071592200_CIT0027"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0028","unstructured":"Dickson S , HornT. Unwrapping the drug pricing mystery and understanding solutions. Fair Pricing Coalition. 2017. http:\/\/www.preventionjustice.org\/wp-content\/uploads\/2017\/01\/Tackling-Drug-Costs-Presentation.pdf. Accessed 31 August 2018."},{"year":"2018","author":"Clinton Health Access Initiative","key":"key\n\t\t\t\t2019031903071592200_CIT0029"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0030","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMp1804306","article-title":"Being PrEPared - preexposure prophylaxis and HIV disparities","volume":"379","author":"Goldstein","year":"2018","journal-title":"N Engl J Med"},{"author":"Centers for Disease Control and Prevention","key":"key\n\t\t\t\t2019031903071592200_CIT0031"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0032","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.annepidem.2018.06.005","article-title":"The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States","volume":"28","author":"Siegler","year":"2018","journal-title":"Ann Epidemiol"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0033","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAI.0000000000001532","article-title":"Estimated coverage to address financial barriers to HIV preexposure prophylaxis among persons with indications for its use, United States, 2015","volume":"76","author":"Smith","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"year":"2018","author":"US Preventive Services Task Force","key":"key\n\t\t\t\t2019031903071592200_CIT0034"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0035","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/cid\/civ1000","article-title":"The Epi-TAF for tenofovir disoproxil fumarate?","volume":"62","author":"Walensky","year":"2016","journal-title":"Clin Infect Dis"},{"author":"US Food and Drug Administration","key":"key\n\t\t\t\t2019031903071592200_CIT0036"},{"year":"2016","author":"IMS Institute for Healthcare Informatics","key":"key\n\t\t\t\t2019031903071592200_CIT0037"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0038","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/M16-1432","article-title":"High generic drug prices and market competition: a retrospective cohort study","volume":"167","author":"Dave","year":"2017","journal-title":"Ann Intern Med"},{"year":"2016","author":"United States Government Accountability Office","key":"key\n\t\t\t\t2019031903071592200_CIT0039"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0040","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1408376","article-title":"High-cost generic drugs\u2013implications for patients and policymakers","volume":"371","author":"Alpern","year":"2014","journal-title":"N Engl J Med"},{"year":"2015","author":"CBS News","key":"key\n\t\t\t\t2019031903071592200_CIT0041"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0042","article-title":"Drug goes from $13.50 a tablet to $750, overnight","author":"Pollack","year":"2015","journal-title":"New York Times"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0043","doi-asserted-by":"crossref","first-page":"e1002473","DOI":"10.1371\/journal.pmed.1002473","article-title":"Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: an evaluation from multi-country surveys and stakeholder interviews","volume":"14","author":"Nurse-Findlay","year":"2017","journal-title":"PLoS Med"},{"author":"CDC","key":"key\n\t\t\t\t2019031903071592200_CIT0044"},{"journal-title":"Ann Intern Med","article-title":"Changes in drug pricing after drug shortages in the United States","author":"Hernandez","key":"key\n\t\t\t\t2019031903071592200_CIT0045"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0046","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/M16-0291","article-title":"Progress in the fight against multidrug-resistant bacteria? A review of U.S. food and drug administration-approved antibiotics, 2010\u20132015","volume":"165","author":"Deak","year":"2016","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0047","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jama.2018.11439","article-title":"Medicare spending on brand-name combination medications vs their generic constituents","volume":"320","author":"Sacks","year":"2018","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019031903071592200_CIT0048","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","author":"Clay","year":"2018","journal-title":"AIDS Res Ther"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz066\/28096344\/jiz066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:21:13Z","timestamp":1606522873000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiz066\/5385524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz066","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published":{"date-parts":[[2019,3,19]]}}}